CZ2001789A3 - Způsob pro in vivo inhibici aktivity ligandu pro osteoprotegerin - Google Patents

Způsob pro in vivo inhibici aktivity ligandu pro osteoprotegerin Download PDF

Info

Publication number
CZ2001789A3
CZ2001789A3 CZ2001789A CZ2001789A CZ2001789A3 CZ 2001789 A3 CZ2001789 A3 CZ 2001789A3 CZ 2001789 A CZ2001789 A CZ 2001789A CZ 2001789 A CZ2001789 A CZ 2001789A CZ 2001789 A3 CZ2001789 A3 CZ 2001789A3
Authority
CZ
Czechia
Prior art keywords
opgl
polypeptide
nucleic acid
animal
modified
Prior art date
Application number
CZ2001789A
Other languages
Czech (cs)
English (en)
Inventor
Torben Halkier
Jesper Haaning
Original Assignee
Pharmexa A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa A/S filed Critical Pharmexa A/S
Publication of CZ2001789A3 publication Critical patent/CZ2001789A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fodder In General (AREA)
CZ2001789A 1998-09-15 1999-09-13 Způsob pro in vivo inhibici aktivity ligandu pro osteoprotegerin CZ2001789A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801164 1998-09-15
US10289698P 1998-10-02 1998-10-02

Publications (1)

Publication Number Publication Date
CZ2001789A3 true CZ2001789A3 (cs) 2001-08-15

Family

ID=26065320

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2001789A CZ2001789A3 (cs) 1998-09-15 1999-09-13 Způsob pro in vivo inhibici aktivity ligandu pro osteoprotegerin

Country Status (24)

Country Link
US (2) US6645500B1 (enExample)
EP (1) EP1114166B1 (enExample)
JP (1) JP2002525060A (enExample)
KR (1) KR100671036B1 (enExample)
CN (1) CN1318105A (enExample)
AT (1) ATE291628T1 (enExample)
AU (1) AU754971B2 (enExample)
CA (1) CA2343654A1 (enExample)
CZ (1) CZ2001789A3 (enExample)
DE (1) DE69924392T2 (enExample)
EE (1) EE200100149A (enExample)
ES (1) ES2239457T3 (enExample)
HK (1) HK1040261A1 (enExample)
HR (1) HRP20010188A2 (enExample)
HU (1) HUP0103578A3 (enExample)
ID (1) ID28386A (enExample)
IL (2) IL141588A0 (enExample)
NO (1) NO20011304L (enExample)
NZ (1) NZ510508A (enExample)
PL (1) PL196790B1 (enExample)
PT (1) PT1114166E (enExample)
SK (1) SK3062001A3 (enExample)
TR (1) TR200100737T2 (enExample)
WO (1) WO2000015807A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ES2284203T5 (es) * 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
CZ2001789A3 (cs) * 1998-09-15 2001-08-15 Pharmexa A/S Způsob pro in vivo inhibici aktivity ligandu pro osteoprotegerin
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
CA2380007A1 (en) * 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
WO2001023559A1 (en) * 1999-09-27 2001-04-05 Eli Lilly And Company Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
ES2248283T3 (es) * 2000-02-21 2006-03-16 Pharmexa A/S Nuevo procedimiento para reducir los niveles de amiloide.
CZ20022748A3 (cs) * 2000-02-21 2004-03-17 Pharmexa A/S Nová metoda regulace obsahu amyloidu
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
MXPA02008144A (es) * 2000-02-23 2002-11-29 Amgen Inc Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
EP1283721A4 (en) * 2000-05-26 2004-07-07 Smithkline Beecham Corp ANTI-RANK-LIGAND-BINDING MONOCLONAL ANTIBODIES USEFUL FOR TREATING DISEASES CAUSED BY THE RANK-LIGANDS
JP2004520011A (ja) * 2000-08-21 2004-07-08 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療において有用な抗−ｒａｎｋリガンドモノクローナル抗体
JPWO2002024228A1 (ja) * 2000-09-21 2004-01-29 株式会社先端科学技術インキュベーションセンター 破骨細胞形成を制御する方法
WO2002024896A2 (en) 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
WO2002080955A1 (en) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
AU2002253133B2 (en) 2001-04-03 2008-02-28 Societe Des Produits Nestle S.A. Osteoprotegerin in milk
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
JP4336467B2 (ja) * 2001-10-15 2009-09-30 株式会社林原生物化学研究所 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
WO2003059281A2 (en) * 2002-01-04 2003-07-24 Xencor Novel variants of rankl protein
JP2005530482A (ja) 2002-01-04 2005-10-13 ゼンコー・インコーポレイテッド ドミナントネガティブタンパク質およびそれらの用法
CA2481074A1 (en) * 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
CA2508773C (en) 2002-12-10 2013-08-27 Schering-Plough Ltd. Canine rankl and methods for preparing and using the same
KR20070058426A (ko) * 2004-06-02 2007-06-08 사이토스 바이오테크놀로지 아게 비-인간 ｔｎｆ-펩티드의 담체 콘쥬게이트의 의학적 용도
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
WO2008088594A2 (en) * 2007-01-12 2008-07-24 Anaptysbio, Inc. Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species
CN101434656B (zh) * 2007-11-16 2011-12-14 首都医科大学 Opg-hsp70融合蛋白的制备方法及用途
WO2009154770A2 (en) * 2008-06-18 2009-12-23 The Texas A & M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
WO2011128892A2 (en) * 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
CN107286244B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
CN107286245B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 Pd-l1和pd-l2重组蛋白及其用途
CN108498786A (zh) * 2018-02-13 2018-09-07 南昌大学第二附属医院 载骨保护素的缓释纳米粒及其制备方法和应用
KR102154637B1 (ko) * 2018-11-12 2020-09-10 조선대학교산학협력단 Rankl의 돌연변이체, 및 이를 포함하는 골다공증 예방 또는 치료용 약학 조성물
WO2024054566A1 (en) * 2022-09-07 2024-03-14 The Regents Of The University Of California Treatment of cancer by blockade of osteoprotegerin
KR20250118303A (ko) * 2024-01-29 2025-08-06 주식회사 아크젠바이오사이온스 Rankl의 돌연변이체 및 이를 포함하는 백신 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5641404A (en) 1993-08-27 1997-06-24 The Dow Chemical Company Process for the separation of enantiomers
EP0755444A4 (en) * 1994-04-01 1998-01-14 Univ Utah MOLECULAR CLONING AND EXPRESSION OF AN INDUCTIBLE PROTEASOME ACTIVATOR BY INTERFERON GAMMA
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
DK1114864T4 (da) * 1996-12-13 2012-09-03 Schering Corp Pattedyrcelleoverfladeantigener samt tilhørende reagenser
CA2274987C (en) * 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
ES2284203T5 (es) * 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
CZ2001789A3 (cs) * 1998-09-15 2001-08-15 Pharmexa A/S Způsob pro in vivo inhibici aktivity ligandu pro osteoprotegerin

Also Published As

Publication number Publication date
US20040115199A1 (en) 2004-06-17
PT1114166E (pt) 2005-08-31
KR100671036B1 (ko) 2007-01-18
NO20011304D0 (no) 2001-03-14
NO20011304L (no) 2001-05-15
DE69924392D1 (de) 2005-04-28
AU754971B2 (en) 2002-11-28
EE200100149A (et) 2002-08-15
JP2002525060A (ja) 2002-08-13
IL141588A0 (en) 2002-03-10
HUP0103578A3 (en) 2005-11-28
HK1040261A1 (zh) 2002-05-31
US6645500B1 (en) 2003-11-11
EP1114166A1 (en) 2001-07-11
ES2239457T3 (es) 2005-09-16
TR200100737T2 (tr) 2001-07-23
CA2343654A1 (en) 2000-03-23
ATE291628T1 (de) 2005-04-15
NZ510508A (en) 2005-05-27
ID28386A (id) 2001-05-17
EP1114166B1 (en) 2005-03-23
HUP0103578A2 (hu) 2002-01-28
KR20010085807A (ko) 2001-09-07
HRP20010188A2 (en) 2002-04-30
WO2000015807A1 (en) 2000-03-23
SK3062001A3 (en) 2002-02-05
DE69924392T2 (de) 2006-03-09
CN1318105A (zh) 2001-10-17
IL141588A (en) 2008-07-08
AU5617399A (en) 2000-04-03
PL196790B1 (pl) 2008-01-31
PL346698A1 (en) 2002-02-25

Similar Documents

Publication Publication Date Title
CZ2001789A3 (cs) Způsob pro in vivo inhibici aktivity ligandu pro osteoprotegerin
KR100750695B1 (ko) Ｇｄｆ-8 활성을 하향-조절하는 방법
KR100731820B1 (ko) 치료적 백신화를 위한 새로운 방법
CZ9903657A3 (cs) Modifikované molekuly TNFalfa, DNA kódující takové modifikované molekuly TNFalfa a vakcíny obsahující uvedené modifikované molekuly TNFalfa
AU2006312847A1 (en) Therapeutic vaccines targeting HMGB1
US20070184023A1 (en) Method for down-regulation of vegf
CZ20013709A3 (cs) Analog interleukinu 5, fragment nukleové kyseliny, vektor, buňka, přípravky a pouľití
US20020172673A1 (en) Method for down-regulating IgE
US20050063952A1 (en) Immunogenic CEA
US7011833B1 (en) Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
WO2006102901A2 (en) Immunogenic egfr peptides comprising foreign t cell stimulating epitope
CN101260152A (zh) 负调节Osteoprotegerin配体活性的方法
EP1541587A2 (en) Method for down-regulating osteoprotegerin ligand activity
WO2008040759A1 (en) Method for down-regulation of cripto
KR20050052499A (ko) 자가 그렐린에 대한 면역화